cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.4071784
title: Research Data for "An alternative analysis of contrast-variation neutron scattering data of casein micelles in semi-deuterated milk" (European Physical Journal E)

description: SANS data used for the analysis in this paper. Original data were published as the FM_s1 set in "Structural heterogeneity of milk casein micelles: a SANS contrast variation study" by Antoine Bouchoux <em>et al</em>. (<em>Soft Matter</em>, 2015, <strong>11</strong>, 389-399) Data were extracted from the figures in this paper using the macOS application GraphClick. The Guinier approximation was then used to rescale the data to the I(Q=0) given in this paper. The files in this data set are two column *.csv files of Q (in Å<sup>–1</sup>) and I(Q) (in cm<sup>–1</sup>). The file names show the proportion of D<sub>2</sub>O in the solvent.
DOI: 10.5281/zenodo.4071783
title: Research Data for "An alternative analysis of contrast-variation neutron scattering data of casein micelles in semi-deuterated milk" (European Physical Journal E)

description: SANS data used for the analysis in this paper. Original data were published as the FM_s1 set in "Structural heterogeneity of milk casein micelles: a SANS contrast variation study" by Antoine Bouchoux <em>et al</em>. (<em>Soft Matter</em>, 2015, <strong>11</strong>, 389-399) Data were extracted from the figures in this paper using the macOS application GraphClick. The Guinier approximation was then used to rescale the data to the I(Q=0) given in this paper. The files in this data set are two column *.csv files of Q (in Å<sup>–1</sup>) and I(Q) (in cm<sup>–1</sup>). The file names show the proportion of D<sub>2</sub>O in the solvent.
DOI: 10.5063/bc3wzs
title: Designcraft for experiments: Solo Surveys

description: A set of remote exercises exploring experimental design for the life sciences. A total of three independent labs were done to focus on different design principles, sampling techniques, and taxa. Exercises are described in full in this open access manual entitled Designcraft for experiments. Data were collected by students in a third-year biology course offering at York University in Toronto, ON, Canada. Students collected the data and published individual datasets to figshare with a CCBY4.0 licensing. Data were then compiled for each lab including balcony birdwatching, backyard bioblitz, and solo surveys by M. Zuliani (ORCID: 0000-0001-8114-3609) and M. Owen (ORCID: 0000-0002-9931-4522). The provenance of each independent observation in the compiled data was recognized by attribution to the initials of the primary data author including citation via DOI and link to figshare.AttributionCJL designed the experiments.Students in course offering collected, innovated, and published individual, primary datasets.MZ, MO, and CJL reviewed the compiled data.MetadataRecord-levelyear is the calendar year of work not termexperiment describes the three experimental options in designcraft booksource is either full experiment or pilot experimentrep is the replicate per experimental setlocation is the site name locallyhabitat is the ecological classificationdate is the calendar date for each observation
DOI: 10.5281/zenodo.4523004
title: Dataset related to article "Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients"

description: This record contains data related to article Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients" <strong>Background: </strong> Allogeneic stem cell transplantation from haploidentical donor using an unmanipulated graft and post-transplantation cyclophosphamide (PT-Cy) is growing. Haploidentical transplantation with PT-Cy showed a major activity in Hodgkin lymphoma (HL), reducing the relapse incidence. The most important predictive factor of survival and toxicity was disease status before transplantation, which was better in patients with well controlled disease. <strong>Methods: </strong> We included 198 HL in complete (CR) or partial remission (PR) before transplantation. Sixty-five patients were transplanted from haploidentical donor and 133 from a HLA identical donor (both sibling and unrelated donors). Survival analysis was defined according to the EBMT criteria. Survival curves were generated by using Kaplan-Meier method and differences between groups were compared by the log rank test or by the log rank test for trend when appropriated. <strong>Results: </strong> The PFS, OS, and RI were significantly better in patients in CR compared to PR (55% vs 29% p = 0.001, 74% vs 55% p = 0.03, 27% vs 55% p &lt; 0.001, respectively). The 2-year PFS was significantly better for HAPLO than HLA-id (63% vs 37%, p = 0.03), without difference in OS. The 1-year NRM was not different. The 2-year relapse incidence (RI) was lower in the HAPLO group (24% vs 44%, p = 0.008). Patients in CR receiving haplo HSCT showed higher 2-year PFS and lower 2-year RI than those allografted with HLA-id donor (75% vs 47%, p &lt; 0.001 and 11% vs 34%, p &lt; 0.001, respectively). In multivariate analysis, donor type and disease status before transplantation were independent predictors of PFS as well as they predict the risk of relapse. Disease status at transplantation and age were independently associated to OS. <strong>Conclusions: </strong> Nonetheless this is a retrospective study, limiting the wide applicability of results, data from this analysis suggest that HLA mismatch can induce a strong graft versus lymphoma effect leading to an enhanced PFS.
DOI: 10.5281/zenodo.4523003
title: Dataset related to article "Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients"

description: This record contains data related to article Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients" <strong>Background: </strong> Allogeneic stem cell transplantation from haploidentical donor using an unmanipulated graft and post-transplantation cyclophosphamide (PT-Cy) is growing. Haploidentical transplantation with PT-Cy showed a major activity in Hodgkin lymphoma (HL), reducing the relapse incidence. The most important predictive factor of survival and toxicity was disease status before transplantation, which was better in patients with well controlled disease. <strong>Methods: </strong> We included 198 HL in complete (CR) or partial remission (PR) before transplantation. Sixty-five patients were transplanted from haploidentical donor and 133 from a HLA identical donor (both sibling and unrelated donors). Survival analysis was defined according to the EBMT criteria. Survival curves were generated by using Kaplan-Meier method and differences between groups were compared by the log rank test or by the log rank test for trend when appropriated. <strong>Results: </strong> The PFS, OS, and RI were significantly better in patients in CR compared to PR (55% vs 29% p = 0.001, 74% vs 55% p = 0.03, 27% vs 55% p &lt; 0.001, respectively). The 2-year PFS was significantly better for HAPLO than HLA-id (63% vs 37%, p = 0.03), without difference in OS. The 1-year NRM was not different. The 2-year relapse incidence (RI) was lower in the HAPLO group (24% vs 44%, p = 0.008). Patients in CR receiving haplo HSCT showed higher 2-year PFS and lower 2-year RI than those allografted with HLA-id donor (75% vs 47%, p &lt; 0.001 and 11% vs 34%, p &lt; 0.001, respectively). In multivariate analysis, donor type and disease status before transplantation were independent predictors of PFS as well as they predict the risk of relapse. Disease status at transplantation and age were independently associated to OS. <strong>Conclusions: </strong> Nonetheless this is a retrospective study, limiting the wide applicability of results, data from this analysis suggest that HLA mismatch can induce a strong graft versus lymphoma effect leading to an enhanced PFS.
DOI: 10.5281/zenodo.4531795
title: Heterogeneous Hardware Support in Docker Images

description: Docker images are commonly used to package, distribute and deploy complex cloud-native applications in containerised form. A container engine executes these applications with separated privileges according to namespaces. Recent studies have investigated security vulnerabilities and runtime characteristics of Docker images. <br> In contrast, little is known about the extent of hardware-dependent features in these images such as processor-specific trusted execution environments, graphics acceleration or extension boards. <br> This problem can be generalised to missing knowledge about the extent of any hardware-specific instructions within the images that may require elevated privileges.<br> In this study, we contribute to increasing this knowledge by a systematic long-term analysis of a sample of Docker images concerning their use of hardware-specific features, including those for virtualisation, acceleration and security. <br> We contribute a Docker registry metadata collector along with augmented metadata covering one-year long of top (i.e., official images and those from the same developers) Docker Hub images, also releasing those as open dataset. <br> Moreover, we provide a heuristic hardware dependency analysis framework and a hardware-aware Docker executor that gives early warnings upon missing hardware dependencies instead of leading to silent or untimely failures. <br> We demonstrate the usefulness of our work for heterogeneous cloud and fog computing environments.
DOI: 10.6084/m9.figshare.8970704
title: Client fish traits underlying variation in service quality in a marine cleaning mutualism

description: Data and analysis script for: Roche DG et al (in prep) <i>Client fish traits underlying variation in service quality in a marine cleaning mutualism</i><br><br>Data collected by DGR and MJ. Please see the readme.txt file for metadata and refer to the manuscript for data collection methods and statistical analyses. For questions or to notify the authors if errors are identified in the data or script, please contact Dominique Roche (dominique.roche@mail.mcgill.ca, dom.g.roche@gmail.com).
DOI: 10.6084/m9.figshare.8970704.v1
title: Client fish traits underlying variation in service quality in a marine cleaning mutualism

description: Data and analysis script for: Roche DG et al (in prep) <i>Client fish traits underlying variation in service quality in a marine cleaning mutualism</i><br><br>Data collected by DGR and MJ. Please see the readme.txt file for metadata and refer to the manuscript for data collection methods and statistical analyses. For questions or to notify the authors if errors are identified in the data or script, please contact Dominique Roche (dominique.roche@mail.mcgill.ca, dom.g.roche@gmail.com).
DOI: 10.5063/6m357v
title: Designcraft for experiments: Balcony Birdwatching

description: A set of remote exercises exploring experimental design for the life sciences. A total of three independent labs were done to focus on different design principles, sampling techniques, and taxa. Exercises are described in full in this open access manual entitled Designcraft for experiments. Data were collected by students in a third-year biology course offering at York University in Toronto, ON, Canada. Students collected the data and published individual datasets to figshare with a CCBY4.0 licensing. Data were then compiled for each lab including balcony birdwatching, backyard bioblitz, and solo surveys by M. Zuliani (ORCID: 0000-0001-8114-3609) and M. Owen (ORCID: 0000-0002-9931-4522). The provenance of each independent observation in the compiled data was recognized by attribution to the initials of the primary data author including citation via DOI and link to figshare.AttributionCJL designed the experiments.Students in course offering collected, innovated, and published individual, primary datasets.MZ, MO, and CJL reviewed the compiled data.MetadataRecord-levelyear is the calendar year of work not termexperiment describes the three experimental options in designcraft booksource is either full experiment or pilot experimentrep is the replicate per experimental setlocation is the site name locallyhabitat is the ecological classificationdate is the calendar date for each observation
DOI: 10.6084/m9.figshare.13868258
title: Yost indexes

description: Here are Yost indexes for census tracts and block groups in the United States for various years from 1990-2019. The Yost index is a composite index of socioeconomic status that consists of a percentile score from 1 (highest SES) to 100 (lowest SES). Data for 1990 and 2000 include the 50 US states plus the District of Columbia. For years after 2000, the data additionally include Puerto Rico. To rescale the index to geographic units smaller than the US, the score column may be used, where scores range from about -1.8 for the highest SES to 1.8 for the lowest SES.<br>More about the Yost index can be found here:<br><br> Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. ​<i>Cancer Causes and Control</i>​ 2001; 12(8): 703–711. <br> Yu M, Tatalovich Z, Gibson JT, Cronin KA. Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. ​<i>Cancer Causes and Control</i>​. 2014; 25(1): 81-92.<br><br><br>
DOI: 10.5281/zenodo.4529127
title: Dataset related to article "Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question"

description: This record contains data related to article "Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question" Abstract <strong>Objectives: </strong>To evaluate the role of stereotactic body radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer. <strong>Methods: </strong>Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression-free survival (PFS), and overall survival (OS). <strong>Results: </strong>From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). LC at 1 and 2 years were 88.9% (95% CI 73.2-98.6) and 73.9% (95% CI 50-87.5), respectively. Median LC was 39.9 months (95% CI 23.3-not reached).PFS rates at 1 and 2 years were 21.9% (95% CI 10.8-35.4) and 10.9% (95% CI 3.4-23.4), respectively. Median PFS was 5.4 months (95%CI 3.1-11.3).OS rates at 1 and 2 years were 79.9% (95% CI 63.7-89.4) and 46.7% (95% CI 29.6-62.2). Median OS was 23 months (95%CI 14.1-31.8). <strong>Conclusions: </strong>Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results. <strong>Advances in knowledge: </strong>Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT.
DOI: 10.5281/zenodo.4529126
title: Dataset related to article "Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question"

description: This record contains data related to article "Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question" Abstract <strong>Objectives: </strong>To evaluate the role of stereotactic body radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer. <strong>Methods: </strong>Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression-free survival (PFS), and overall survival (OS). <strong>Results: </strong>From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). LC at 1 and 2 years were 88.9% (95% CI 73.2-98.6) and 73.9% (95% CI 50-87.5), respectively. Median LC was 39.9 months (95% CI 23.3-not reached).PFS rates at 1 and 2 years were 21.9% (95% CI 10.8-35.4) and 10.9% (95% CI 3.4-23.4), respectively. Median PFS was 5.4 months (95%CI 3.1-11.3).OS rates at 1 and 2 years were 79.9% (95% CI 63.7-89.4) and 46.7% (95% CI 29.6-62.2). Median OS was 23 months (95%CI 14.1-31.8). <strong>Conclusions: </strong>Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results. <strong>Advances in knowledge: </strong>Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT.
DOI: 10.15468/xh3mpy
title: Una nueva especie de Eraina Clarke (Lepidoptera: Autostichidae) de Chile Central

description: This dataset contains the digitized treatments in Plazi based on the original journal article Urra, Francisco (2017): Una nueva especie de Eraina Clarke (Lepidoptera: Autostichidae) de Chile Central. Insecta Mundi 2017 (524): 1-5, DOI: http://doi.org/10.5281/zenodo.4531813
DOI: 10.15468/ums9u3
title: Three new species and one newly recorded species of genus Frisilia Walker (Lepidoptera, Lecithoceridae) from China, with a checklist of the world

description: This dataset contains the digitized treatments in Plazi based on the original journal article Yu, Shuai, Wang, Shuxia (2021): Three new species and one newly recorded species of genus Frisilia Walker (Lepidoptera, Lecithoceridae) from China, with a checklist of the world. Zootaxa 4926 (1): 65-78, DOI: https://doi.org/10.11646/zootaxa.4926.1.4
DOI: 10.5281/zenodo.4529151
title: Dataset related to article "Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis"

description: This record contains data related to article "Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis". In this pilot study, we describe our experience with vismodegib in the treatment of basal cell carcinoma (BCC) and evaluate the feasibility of a tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced BCC. We retrospectively analyzed the clinical charts of 17 consecutive patients with BCC who were treated with vismodegib. Therapy was started at the usual dosage of 150 mg per day per person, continuously; a rescheduled dosage of 150 mg per day for 4 weeks with a subsequent stop of 2 weeks was allowed during the treatment according to the standard practice of our institution. During treatment, 14 patients with responsive disease presented an adverse event (100% cramps and 20% dysgeusia), therefore, requiring a change in the treatment plan. Overall, in eight out of 17 patients (47% of the overall population), it was possible to re-schedule the treatment by postponing therapy for 2 weeks every 4 weeks. These patients were all still alive at the time of the present analysis and were showing complete response. Adverse events resolved during the first interruption of therapy. The intermittent vismodegib schedule assessed in this pilot series could be beneficial in improving duration of treatment, allowing to maintain a long-term treatment response, even in an elderly and fragile population. Based on these preliminary findings, dedicated studies may be planned to further evaluate an intermittent schedule of vismodegib administration
DOI: 10.5281/zenodo.4529150
title: Dataset related to article "Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis"

description: This record contains data related to article "Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis". In this pilot study, we describe our experience with vismodegib in the treatment of basal cell carcinoma (BCC) and evaluate the feasibility of a tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced BCC. We retrospectively analyzed the clinical charts of 17 consecutive patients with BCC who were treated with vismodegib. Therapy was started at the usual dosage of 150 mg per day per person, continuously; a rescheduled dosage of 150 mg per day for 4 weeks with a subsequent stop of 2 weeks was allowed during the treatment according to the standard practice of our institution. During treatment, 14 patients with responsive disease presented an adverse event (100% cramps and 20% dysgeusia), therefore, requiring a change in the treatment plan. Overall, in eight out of 17 patients (47% of the overall population), it was possible to re-schedule the treatment by postponing therapy for 2 weeks every 4 weeks. These patients were all still alive at the time of the present analysis and were showing complete response. Adverse events resolved during the first interruption of therapy. The intermittent vismodegib schedule assessed in this pilot series could be beneficial in improving duration of treatment, allowing to maintain a long-term treatment response, even in an elderly and fragile population. Based on these preliminary findings, dedicated studies may be planned to further evaluate an intermittent schedule of vismodegib administration